Man 1-2 Man-PEGylated Derivative as a Tool for in vitro and in vivo Dendritic Cell Targeting
- Technology Benefits
- The approach:ΓÇóIs highly cost effective and is capable of operating at a much larger scaleΓÇóAllows for a higher percentage of specific binding as compared to prior-art proceduresΓÇóAllows for an improved delivery of compounds as compared to conventional approachesΓÇóTriggers a desired response in dendritic cells, leading to their timely activationΓÇóAllows for an effective regulation of the immune system as compared to conventional approachesΓÇóUses liposomes that are stable and slightly negatively charged as compared to conventional approachesΓÇóWould be commercially useful for treating various disorders such as HIV, HBV, HCV, herpes viruses, autoimmune disorders, transplant rejection, and cancer
- Detailed Technology Description
- None
- *Abstract
-
Currently, few immune system targeting delivery mechanisms are available. Most of these mechanisms use complex chemistry, making it difficult to identify exact binding percentages. Furthermore, many such procedures even use bromination and de-bromination techniques, making the procedure more expensive, multi-stepped, and with reduced yield. This approach discloses the development and use of novel compounds to effectively target dendritic cells.
- *Principal Investigator
-
Name: Tatyana Levchenko
Department:
Name: Juan Sebestian Pappalardo
Department:
Name: Stefano Salmaso
Department:
Name: Micaela Toniutti
Department:
Name: Vladmir Torchillin
Department:
- Country/Region
- USA
For more information, please click Here
